Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Enable superior drug development and patient care decision-making through model-informed drug development, regulatory science, real world evidence and knowledge integration, thus optimizing R&D productivity, commercial value and patient outcomes.

Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Latest from Certara

Blog

Building an Early Development Strategy for Complex Biologics

Integrating Organ-on-Chips & In Silico Models for Translational Pharmacology Applications

Certara Scientists Support TB Alliance’s Groundbreaking New Drug

In the Press

Certara Introduces Hasharc Decentralized Application for Healthcare at Hedera Hashgraph Open Access Launch

Certara Launches Version 8.2 of its Industry-leading Phoenix PK/PD Modeling and Simulation Software for Drug…

Certara Launches BaseCase Data Manager to Enhance Value-based Customer Presentations

Webinars

How to Optimize Your Drug Label Using Biosimulation Methodology

Using PopPK Modeling to Optimize Dosing in Patients with Organ Impairment

A New Method to Quantify Population Variability for Toxicity Testing

Changing the Game in Drug Development and Patient Access

Model-informed Drug Development Health Economics/Outcomes Research & Real World Evidence Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Latest from Certara

Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services